Organic Process Research & Development 2011, 15, 64–72
Kilogram Synthesis of a Second-Generation LFA-1/ICAM Inhibitor
Albert J. DelMonte,* Yu Fan, Kevin P. Girard, Gregory S. Jones, Robert E. Waltermire, Victor Rosso, and Xuebao Wang
Process Research and DeVelopment, Bristol-Myers Squibb Company, One Squibb DriVe, P.O. Box 191, New Brunswick,
New Jersey 08903-0191, United States
Abstract:
Results and Discussions
The original synthesis of 1 by our Discovery colleagues
provided the initial quantities required for some of the preclinical
development studies (Scheme 1).4 The generation of tert-butyl
nicotinic ester 3 was achieved by formation of the acid chloride
via the use of thionyl chloride and subsequent treatment with
tert-butanol. Following the workup, the reaction mixture was
dried with Na2SO4 and concentrated via rotovap to afford 3 as
a yellow solid. Treating the spirocyclic hydantoin 4a with a
slight excess of 3 at 112 °C for 18 h in the presence of DIPEA
afforded the desired N-alkylated product 5a. Addition of a
solution of 5a into cold H2O resulted in precipitation of a crude
solid which was subsequently chromatographed to remove
1-3% of the isopropyl ester analogue 6 (Figure 1). Impurity 6
resulted from low levels of isopropanol present in the tert-
butanol used to prepare 3.5 Purified 5a was then deprotected
utilizing a 1:1 trifluoroacetic acid:dichloromethane solvent
system, and after an extractive workup, was concentrated to
dryness. The crude material was subsequently dissolved in hot
chloroform and the desired product 1 was isolated in two crops.
Unfortunately residual chloroform (0.04%) made this material
unsuitable for toxicology studies.
A modified synthesis of 1 (Scheme 2) was developed by
our Discovery scale-up group colleagues to address the iso-
propyl ester impurity as well as the residual chloroform issue
in order to supply multigram quantities for preclinical develop-
ment studies.6 In this modified approach, the 6-chloronicotinic
acid 2 was protected in situ with TMSCl, and the resulting
intermediate 7 was coupled with hydantoin 4a. The reaction
mixture containing intermediate 8 was treated with MeOH, and
crude 1 was directly isolated from the reaction mixture upon
addition of water. Crude 1 was recrystallized from EtOH/H2O
to afford the desired 1 in high purity and yield (99.5 HPLC
area percent purity, >99.9% ee, and 89% overall yield).
While the modified approach was attractive for producing
multigram quantities of API quickly, we had concerns that the
extensive telescope which affords 1 directly provides little
control over any potential impurities that might be introduced
from the raw materials. From an impurity control perspective,
The process development and the kilogram-scale synthesis of BMS-
688521 (1) are described. The synthesis features a highly efficient
telescoped sequence which utilizes previously described spirocyclic
hydantoin (4b) to produce the final intermediate via an SNAR
reaction. A final deprotection step affords BMS-688521 (1) in high
quality with an overall yield of 65% from the key intermediate,
spirocyclic hydantoin (4b).
Introduction
A key feature of the intercellular immune response is that
cytokine stimulated cells express LFA-1 (leukocyte function-
associated antigen-1) on their surface. LFA-1 then interacts with
ICAM (intercellular adhesion molecule), which is found on the
surfaces of both leukocytes and endothelium. This interaction
facilitates T-cell adhesion and migration through the blood
vessel wall to the inflamed area.1 Small molecules which
successfully inhibit the LFA-1/ICAM interaction have potential
as drugs for the treatment of a variety of autoimmune and
inflammatory diseases such as rheumatoid arthritis and psoriasis.2,3
The LFA-1 receptor antagonist, BMS-688521, 1, was a second
generation molecule selected for clinical development and we
required a synthesis that would reliably generate kilogram
quantities of API. This contribution details the identification
and development of a synthesis which enabled the realization
of this goal.
* Author for correspondence. E-mail: albert.delmonte@bms.com.
(1) For a discussion on the inhibition of LFA-1/ICAM-1as an approach
to treating autoimmune diseases see: Yusuf-Makagiansar, H.; Ander-
son, M. E.; Yakovleva, T. V.; Murray, J. S.; Siahaan, T. J. Med. Res.
ReV. 2002, 22, 146.
(2) For a discussion of therapeutic options for treatment of psoriasis, see:
Gottlieb, A. B. J. Acad. Dermatol 2005, 53, S3. Larson, R. S.; Davis,
T.; Bologa, C.; Semenuk, G.; Vijayan, S.; Li, Y.; Oprea, T.; Chigaev,
A.; Buranda, T.; Wagner, C. R.; Sklar, L. A.
(3) For other small-molecule LFA-1/ICAM-1 antagonists as potential drugs
please see: (a) Pei, Z.; Xin, Z.; Liu, G.; Li, Y.; Reilly, E. B.; Lubbers,
N. L.; Huth, J. R.; Link, J. T.; von Geldern, T. W.; Cox, B. F.; Leitza,
S.; Gao, Y.; Marsh, K. C.; DeVries, P.; Okasinski, G. F. J. Med. Chem.
2001, 44, 2913. (b) Liu, G.; Huth, J. R.; Olejniczak, E. T.; Mendoza,
R.; DeVries, P.; Leitza, S.; Reilly, E. B.; Olasinski, G. F.; Fesik, S. W.;
von Geldern, T. W. J. Med. Chem. 2001, 44, 1202. (c) Wu, J.-P.;
Emeigh, J.; Gao, D. A.; Goldberg, D. R.; Kuzmich, D.; Miao, C.;
Potocki, I.; Qian, K. C.; Sorcek, R. J.; Jeanfavre, D. D.; Kishimoto,
K.; Mainolfi, E. A.; Nabozny, G.; Peng, C.; Reilly, P; Rothlein, R.;
Sellati, R. H.; Woska, J. R.; Chen, S.; Gunn, J. A.; O’Brien, D.; Norris,
S. H.; Kelly, T. A. J. Med. Chem. 2004, 47, 5356. (d) Last-Barney,
K.; Davidson, W.; Cardozo, M.; Frye, L. L.; Grygon, C. a.; Hopkins,
J. L.; Jeanfavre, D. D.; Pav, S.; Qian, C.; Stevenson, J. M.; Tong, L.;
Zindell, R.; Kelly, T. A. J. Am. Chem. Soc. 2001, 123, 5643. (e) Wang,
G. T.; Wang, S.; Gentles, R.; Sowin, T.; Leitza, S.; Reilly, E. B.; von
Geldern, T. W. Bioorg. Med. Chem. Lett. 2005, 15, 195. (f) Wattanasin,
S.; Albert, R.; Ehrhardt, C.; Roche, D.; Savio, M.; Hommel, U.;
Welzenbach, K.; Weitz-Schmidt, G. Bioorg. Med. Chem. Lett. 2003,
12, 499.
(4) Watterson, S. H.; Xiao, Z.; Dodd, D. S.; Tortolani, D. R.; Vaccaro,
W.; Potin, D.; Launay, M.; Stetsko, D. K.; Skala, S.; Davis, P. M.;
Lee, D.; Yang, X.; McIntyre, K. W.; Balimane, R.; Patel, K.; Yang,
Z.; Marathe, P.; Kadiyala, P.; Tebben, A. J.; Sheriff, S.; Chang,
C. Y. Y.; Ziemba, T.; Zhang, H.; Chen, B.-C.; DelMonte, A. J.;
Aranibar, N.; McKinnon, M.; Barrish, J. C.; Suchard, S. J.; Dhar,
T. G. M. J. Med. Chem. 2010, 53, 3814.
(5) Due to the higher level of reactivity of isopropanol relative to that of
tert-butanol, the isopropyl impurity 6 is enriched to a higher level
than the level of isopropanol observed in the tert-butanol.
(6) Zhang, H.; Watterson, S. H.; Xiao, Z.; Dhar, T. G. M.; Balasubra-
manian, B.; Barrish, J. C.; Chen, B.-C. Org. Process Res. DeV. 2010,
14, 936.
64
•
Vol. 15, No. 1, 2011 / Organic Process Research & Development
10.1021/op100225g 2011 American Chemical Society
Published on Web 11/29/2010